Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

(2013) B. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

(2012) Tadeusz Robak et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Optimization of current and future therapy for autoimmune diseases

(2012) Lawrence Steinman et al.   NATURE MEDICINE

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling

(2011) Arvin C. Dar et al.   Annual Review of Biochemistry

The many faces of Janus kinase

(2011) Matthew M. Seavey et al.   BIOCHEMICAL PHARMACOLOGY

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

(2011) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Th1 and Th17 cells

(2010) Jesse M. Damsker et al.   Annals of the New York Academy of Sciences

Syk kinase inhibitors for rheumatoid arthritis: Trials and tribulations

(2010) Maarten Boers   ARTHRITIS AND RHEUMATISM

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

(2010) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease

(2010) I. Dotan et al.   GUT

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Multitude of Kinases—Which are the Best Targets in Treating Rheumatoid Arthritis?

(2010) Tamsin M. Lindstrom et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

(2009) Nemanja Damjanov et al.   ARTHRITIS AND RHEUMATISM

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Understanding autoimmune disease: new targets for drug discovery

(2009) Cristina Balagué et al.   DRUG DISCOVERY TODAY

A novel Syk kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011

(2009) Peter Norman   EXPERT OPINION ON THERAPEUTIC PATENTS

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Reversible Phosphorylation of Histidine Residues in Proteins from Vertebrates

(2009) S. Klumpp et al.   Science Signaling

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Therapeutic Protein Kinase Inhibitors

(2008) S. K. Grant   CELLULAR AND MOLECULAR LIFE SCIENCES

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

Kinase inhibitors for the treatment of inflammatory and autoimmune disorders

(2008) Shripad S. Bhagwat   Purinergic Signalling

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

(2008) Anthony J Milici et al.   ARTHRITIS RESEARCH & THERAPY